Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared an article by Jens Hoeppner, et al. on LinkedIn:
“Perioperative chemo (FLOT) outperforms preop chemoradiotherapy (CRT) for resectable esophageal adenocarcinoma!
- 3-year OS**: 57.4% (FLOT) vs. 50.7%
- Grade 3+ adverse events**: 58% (FLOT) vs. 50%
- 90-day mortality**: 3.1% (FLOT) vs. 5.6%
FLOT shows better survival outcomes! “
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.
Authors: Jens Hoeppner, et al.
